Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=51132#.VFbVrmfHRK0
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=51132#.VFbVrmfHRK0
Author(s)
1Department of Biological Sciences, Texas A&M University, College Station, USA.
2Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, USA.
3Department of Biochemistry, Molecular Biology, Entomology and Plant Pathology, Mississippi State University, USA.
4Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, USA.
2Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, USA.
3Department of Biochemistry, Molecular Biology, Entomology and Plant Pathology, Mississippi State University, USA.
4Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, USA.
Occidiofungin, a glyco-lipopeptide obtained from the liquid culture of Burkholderia contaminans
MS14, has been identified as a novel fungicide. The natural product was
shown to have a minimal amount of toxicity in a previous mouse toxicity
study following intraperitoneal and subcutaneous administration. In
this study, the toxicity of occidiofungin was evaluated following a 5
mg/kg intravenous tail vein injection. In addition, the toxicity of
occidiofungin was evaluated against human fibroblast and cancer cell
lines. Weight loss was the most significant observation following
intravenous administration of occidiofungin. Histology, hematology, and
blood serum chemistry did not reveal any significant signs of toxicity.
The activity observed in the in vitro cytotoxicity assay against
the cancer cell lines was all below 75 nM concentration of
occidiofungin. To date, the potency of occidiofungin against these
cancer cell lines is greater than any activity observed against fungi.
The findings in this study support the need to further evaluate
occidiofungin’s chemotherapeutic potential.
KEYWORDS
Cite this paper
Hing, S. , Ravichandran, A. , Escano, J. , Cooley,
J. , Austin, F. , Lu, S. , Pruett, S. and Smith, L. (2014)
Toxicological Evaluation of Occidiofungin against Mice and Human Cancer
Cell Lines. Pharmacology & Pharmacy, 5, 1085-1093. doi: 10.4236/pp.2014.511118.
| [1] |
Ellis, D., Gosai, J., Emrick,
C., Heintz, R., Romans, L., Gordon, D., Lu, S., Austin, F. and Smith, L.
(2012) Occidiofungin’s Chemical Stability and in Vitro Potency against
Candida species. Antimicrob Agents Chemother, 56, 765-769. http://dx.doi.org/10.1128/AAC.05231-11 |
| [2] |
Emrick, D., Ravichandran, A.,
Gosai, J., Lu, S., Gordon, D.M. and Smith, L. (2013) The Antifungal
Occidiofungin Triggers an Apoptotic Mechanism of Cell Death in Yeast.
Journal of Natural Products, 76, 829-838. http://dx.doi.org/10.1021/np300678e |
| [3] | Gu, G., Lu, S. and Wang, N. (2008) AmbR1 and AmbR2 Are Two Transcriptional Regulators Essential for the Antifungal Activity of Burkholderia sp Strain MS14. Phytopathology, 98, S63-S63. |
| [4] |
Gu, G., Smith, L., Liu, A. and
Lu, S.-E. (2011) A genetic and Biochemical Map for the Biosynthesis of
Occidiofungin, an Antifungal Produced by Burkholderia contaminans Strain
MS14. Applied and Environmental Microbiology, 77, 6189-6198. http://dx.doi.org/10.1128/AEM.00377-11 |
| [5] |
Gu, G., Wang, N., Chaney, N.,
Smith, L. and Lu, S.-E. (2009) AmbR1 is a Key Transcriptional Regulator
for Production of Antifungal Activity of Burkholderia contaminans Strain
MS14. FEMS Microbiology Letters, 297, 54-60. http://dx.doi.org/10.1111/j.1574-6968.2009.01653.x |
| [6] |
Gu, G. Y., Smith, L., Wang, N.,
Wang, H. and Lu, S.E. (2009) Biosynthesis of an Antifungal Oligopeptide
in Burkholderia contaminans Strain MS14. Biochemical and Biophysical
Research Communications, 380, 328-332. http://dx.doi.org/10.1016/j.bbrc.2009.01.073 |
| [7] |
Lu, S.-E., Novak, J., Austin, F.
W., Gu, G., Ellis, D., Kirk, M., Wilson-Stanford, S., Tonelli, M. and
Smith, L. (2009) Occidiofungin, a Unique Antifungal Glycopeptide
Produced by a Strain of Burkholderia contaminans. Biochemistry, 48,
8312. http://dx.doi.org/10.1021/bi900814c |
| [8] |
Ravichandran, A., Gu, G.,
Escano, J., Lu, S.-E. and Smith, L. (2013) The Presence of Two Cyclase
Thioesterases Expands the Conformational Freedom of the Cyclic Peptide
Occidiofungin. Journal of Natural Products, 76, 150-156. http://dx.doi.org/10.1021/np3005503 |
| [9] |
Clancy, C.J., Huang, H., Cheng,
S., Derendorf, H. and Nguyen, M.H. (2006) Characterizing the Effects of
Caspofungin on Candida albicans, Candida parapsilosis and Candida
glabrata Isolates by Simultaneous Time-Kill and Postantifungal-Effect
Experiments. Antimicrobial Agents and Chemotherapy, 50, 2569-2572. http://dx.doi.org/10.1128/AAC.00291-06 |
| [10] | Ernst, E.J., Klepser, M.E. and Pfaller, M.A. (2000) Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 44, 1108-1111. http://dx.doi.org/10.1128/AAC.44.4.1108-1111.2000 |
| [11] |
Wei, T., Cooley, J., Austin, F.,
Lu, S., Smith, L. and Pruett, S. (2012) Nonclinical Toxicological
Evaluation of Occidiofungin, a Unique Glycolipopeptide Antifungal.
International Journal of Toxicology, 31, 326-336. http://dx.doi.org/10.1177/1091581812445185 |
| [12] |
Luster, M.I., Portier, C., Pait,
D.G., White Jr., K.L., Gennings, C., Munson, A.E. and Rosenthal, G.J.
(1992) Risk Assessment in Immunotoxicology I. Sensitivity and
Predictability of Immune Tests. Fundamental and Applied Toxicology:
Official Journal of the Society of Toxicology, 18, 200-210. http://dx.doi.org/10.1093/toxsci/18.2.200 |
| [13] |
Loftsson, T. and Brewster, M.E.
(2012) Cyclodextrins as Functional Excipients: Methods to Enhance
Complexation Efficiency. Journal of Pharmaceutical Sciences, 101,
3019-3032. http://dx.doi.org/10.1002/jps.23077 |
| [14] |
Germolec, D.R., Kashon, M.,
Nyska, A., Kuper, C.F., Portier, C., Kommineni, C., Johnson, K.A. and
Luster, M.I. (2004) The Accuracy of Extended Histopathology to Detect
Immunotoxic Chemicals. Toxicological Sciences: An Official Journal of
the Society of Toxicology, 82, 504-514. http://dx.doi.org/10.1093/toxsci/kfh271 |
| [15] |
Gabay, C., Ben-Bassat, H.,
Schlesinger, M. and Laskov, R. (1999) Somatic Mutations and Intraclonal
Variations in the Rearranged Vκ Genes of B-Non-Hodgkin’s Lymphoma Cell
Lines. European Journal of Haematology, 63, 180-191. http://dx.doi.org/10.1111/j.1600-0609.1999.tb01766.x |
| [16] | Hamilton, T.C., Young, R.C. and Ozols, R.F. (1984) Experimental Model Systems of Ovarian Cancer: Applications to the Design and Evaluation of New Treatment Ap-proaches. Seminars in Oncology, 11, 285-298. |
| [17] | Wright, W.C., Daniels, W.P. and Fogh, J. (1981) Distinction of Seventy-One Cultured Human Tumor Cell Lines by Polymorphic Enzyme Analysis. Journal of the National Cancer Institute, 66, 239-247. |
| [18] |
Roccaro, A.M., Hideshima, T.,
Richardson, P.G., Russo, D., Ribatti, D., Vacca, A., Dammacco, F. and
Anderson, K.C. (2006) Bortezomib as an Antitumor Agent. Current
Pharmaceutical Biotechnology, 7, 441-448. http://dx.doi.org/10.2174/138920106779116865 |
| [19] |
Tobinai, K. (2007) Proteasome
Inhibitor, Bortezomib, for Myeloma and Lymphoma. International Journal
of Clinical Oncology, 12, 318-326. http://dx.doi.org/10.1007/s10147-007-0695-5 |
| [20] |
Cavo, M. (2006) Proteasome
Inhibitor Bortezomib for the Treatment of Multiple Myeloma. Leukemia,
20, 1341-1352. http://dx.doi.org/10.1038/sj.leu.2404278 |
| [21] |
Chauhan, D., Hideshima, T.,
Mitsiades, C., Richardson, P. and Anderson, K.C. (2005) Proteasome
Inhibitor Therapy in Multiple Myeloma. Molecular Cancer Therapeutics, 4,
686-692. http://dx.doi.org/10.1158/1535-7163.MCT-04-0338 |
| [22] | Anderson, K.C. (2004) Bortezomib Therapy for Myeloma. Current Hematology Reports, 3, 65-65. |
| [23] |
Anderson, K.C. (2007) Targeted
Therapy of Multiple Myeloma Based upon Tumor-Microenvironmental
Interactions. Experimental Hematology, 35, 155-162. http://dx.doi.org/10.1016/j.exphem.2007.01.024 |
| [24] | Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. and Elliott, P.J. (1999) Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents. Cancer Research, 59, 2615-2622. |
| [25] | Fuchs, B.A. and Pruett, S.B. (1993) Morphine Induces Apoptosis in Murine Thymocytes in Vivo but Not in Vitro: Involvement of both Opiate and Glucocorticoid Receptors. The Journal of Pharmacology and Experimental Therapeutics, 266, 417-423. |
| [26] |
Demain, A.L. and Vaishnav, P.
(2011) Natural Products for Cancer Chemotherapy. Microbial
Biotechnology, 4, 687-699. http://dx.doi.org/10.1111/j.1751-7915.2010.00221.x eww141103lx |
评论
发表评论